What is BPC-157? Origin, research and regulatory status
BPC-157 is a synthetic peptide made of 15 amino acids. Its sequence is taken from a larger protein that researchers found in human gastric juice. Since the early 1990s, BPC-157 has been studied in hundreds of animal and cell experiments, mostly on tissue repair in tendons, muscles and the gut. Human data, however, is still very limited. This overview explains where the peptide comes from, what the research shows so far and where the open questions are.
What is BPC-157
BPC-157 is a synthetic peptide made of 15 amino acids. Its sequence is taken from a larger protein that researchers found in human gastric juice. Since the early 1990s, BPC-157 has been studied in hundreds of animal and cell experiments, mostly on tissue repair in tendons, muscles and the gut. Human data, however, is still very limited. This overview explains where the peptide comes from, what the research shows so far and where the open questions are.
Where BPC-157 comes from
The name BPC stands for "Body Protection Compound". A research group at the University of Zagreb, led by Predrag Sikiric, isolated a protein from gastric juice that seemed to protect the stomach lining in animal models. BPC-157 is a short fragment of this protein, 15 amino acids long, that the group synthesised and tested on its own.
The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. With a molecular weight of about 1,419 Da, BPC-157 is a small molecule compared to proteins. One property makes it unusual among peptides: it is stable in gastric juice for longer than most peptides, which normally break down there within minutes. This is the reason why researchers have tested it both orally and by injection in animals.
What the BPC-157 research looks at
Most BPC-157 studies come from the same Zagreb group, and almost all of them use rats or mice. The main research areas are:
Tendons and ligaments: healing of cut or crushed tendons in rats
Muscle: recovery after muscle injury in animal models
Gastrointestinal tract: ulcers, fistulas and inflammation of the gut lining
Blood vessels: formation of new blood vessels (angiogenesis) and the nitric oxide system
A frequently cited cell study is Chang et al. (2011) in the Journal of Applied Physiology. The researchers found that BPC-157 increased the outgrowth, survival and migration of tendon fibroblasts in cell culture. Fibroblasts are the cells that build new connective tissue. A review by Seiwerth et al. (2018) in Current Pharmaceutical Design summarises how BPC-157 interacts with growth factors that control blood vessel formation.
How researchers think BPC-157 works
The exact mechanism of BPC-157 is not fully understood. The published papers point to several pathways. BPC-157 appears to influence the expression of growth factor receptors (for example VEGFR2), to interact with the nitric oxide system and to support the migration of cells into damaged tissue. These findings come from cell cultures and animals. It is not yet clear which of them are relevant in humans.
How strong is the evidence for BPC-157?
This is the most important question, and the answer is clear: the evidence base for BPC-157 is almost entirely preclinical. A systematic review by Gwyer, Wragg and Wilson (2019) in Cell and Tissue Research looked at BPC-157 and musculoskeletal soft tissue healing. The authors found consistently positive results in animal studies, but they also pointed out that controlled human trials are missing.
Several limitations are worth knowing when you read about BPC-157:
Most studies come from one research group, and independent replication is limited.
Rodent models do not always translate to humans.
There are no large, randomised, placebo-controlled human trials.
Long-term safety data in humans does not exist.
Many claims about BPC-157 online go far beyond what the studies show. A careful reading of the literature supports the statement that BPC-157 is an interesting research compound. It does not support claims of proven effects in people.
BPC-157 legal and regulatory status
BPC-157 is not approved as a medicine by the FDA, the EMA or any other major drug authority. In 2023, the FDA placed BPC-157 on its list of bulk substances with potential safety concerns, which means that US compounding pharmacies may not use it.
In sport, the status is also clear. The World Anti-Doping Agency (WADA) has listed BPC-157 under section S0 "Non-approved substances" of its Prohibited List since 2022. It is banned at all times, in and out of competition.
In most countries, BPC-157 is sold as a research chemical for laboratory use only. It is not intended for human consumption.
BPC-157 compared to other repair peptides
BPC-157 is often mentioned together with TB-500, a synthetic fragment of the protein thymosin beta-4. Both are studied in the context of tissue repair, but they come from different proteins and seem to act through different mechanisms. We explain the differences in detail in our article BPC-157 vs TB-500. For researchers who want to work with both compounds, a BPC-157 / TB-500 blend is also available.
A third peptide in the same research field is GHK-Cu, a copper peptide that is studied mainly for skin and connective tissue. You can read more about it in our GHK-Cu guide.
How labs store and handle BPC-157
BPC-157 is supplied as a lyophilised (freeze-dried) powder. In this form it is relatively stable. Labs usually store the sealed vial in a freezer at -20 °C for long-term storage, or in a refrigerator at 2 to 8 °C for shorter periods. Protection from light and moisture is important.
Before use, the powder is dissolved in a sterile solvent, usually bacteriostatic water. After reconstitution, the solution is stored in the refrigerator and used within a limited time. The exact steps and the concentration calculation are explained in our guide on how to reconstitute peptides.
Our BPC-157 10 mg is supplied as lyophilised powder for laboratory research.
Frequently asked questions about BPC-157
Is BPC-157 a natural substance?
Is BPC-157 banned in sports?
Are there human studies on BPC-157?
Is BPC-157 approved as a medicine?
Sources
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. doi:10.1152/japplphysiol.00945.2010
Seiwerth S, Rucman R, Turkovic B, et al. (2018). BPC 157 and standard angiogenic growth factors. Current Pharmaceutical Design. doi:10.2174/1381612824666180712110447
Gwyer D, Wragg NM, Wilson SL (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. doi:10.1007/s00441-019-03016-8
World Anti-Doping Agency. Prohibited List. wada-ama.org
This article summarises published research for information only. It is not medical advice. All products on this site are sold for laboratory research use only and are not intended for human or veterinary use.
